Comparative Pharmacology
Head-to-head clinical analysis: DODEX versus RUBIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DODEX versus RUBIVITE.
DODEX vs RUBIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a synthetic form of vitamin B12, which acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, erythrocyte maturation, and neurological function. In cyanide poisoning, it binds cyanide ions to form nontoxic cyanocobalamin, which is excreted renally.
1 mg intramuscularly once every 7-10 days for maintenance; 1 mg intramuscularly once daily for 7 days for initial treatment.
1000 mcg intramuscularly or deep subcutaneous injection once daily for 5-7 days, then 100-1000 mcg monthly for maintenance.
None Documented
None Documented
Terminal elimination half-life is approximately 6 days (range 4-10 days) in plasma; however, due to extensive tissue binding and enterohepatic recirculation, the pharmacodynamic half-life for correction of deficiency is about 1 year.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 24-48 hours in severe impairment)
Primarily renal: ~50-80% of absorbed dose excreted unchanged in urine via glomerular filtration. Biliary/fecal excretion accounts for <10% as cyanocobalamin.
Primarily renal; ~50-80% of absorbed dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for minor fraction (<10%)
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement